8G2M

The tumor activated anti-CTLA-4 monoclonal antibody XTX101 demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer

Summary for 8G2M

• Entry DOI: 10.2210/pdb8g2m/pdb
• Descriptor: masking peptide, Heavy chain of humanized IgG, Light chain of humanized IgG, ... (5 entities in total)
• Functional Keywords: engineered antibody, immune system
• Biological source: Mus musculus; More
• Total number of polymer chains: 3
• Total formula weight: 47103.47

Authors

Williams, J.C.,Williams, J.C. (deposition date: 2023-02-05, release date: 2024-02-14)

• Primary citation: Jenkins, K.A.,Park, M.,Pederzoli-Ribeil, M.,Eskiocak, U.,Johnson, P.,Guzman, W.,McLaughlin, M.,Moore-Lai, D.,O'Toole, C.,Liu, Z.,Nicholson, B.,Flesch, V.,Qiu, H.,Clackson, T.,O'Hagan, R.C.,Rodeck, U.,Karow, M.,O'Neil, J.,Williams, J.C.; XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.; J Immunother Cancer, 11:-, 2023; PubMed: 38164757; DOI: 10.1136/jitc-2023-007785

Experimental method

X-RAY DIFFRACTION (1.8 Å)